Jacqualyn Fouse joined Dermavant Sciences in July 2017. Dr. Fouse previously served as President and Chief Operating Officer of Celgene Corporation until April 2017, and as a member of Celgene’s Board of Directors through June 2017. She joined Celgene in 2010 as Chief Financial Officer and was named president of the company’s global Hematology & Oncology franchise in 2014. Her experience at Celgene included working closely with the business unit that launched OTEZLA® for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
Before joining Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited, a leading global agribusiness and food company. Prior to Bunge, she served as Senior Vice President, Chief Financial Officer, and Head of Corporate Strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her time with Alcon she held a variety of senior leadership roles with international companies and spent almost a decade of her career in Switzerland. Dr. Fouse earned her B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington.
Vince Ippolito joined Dermavant in September 2017. He has over thirty years of experience in the pharmaceutical industry, including twenty years in dermatology. He most recently served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-focused biopharmaceutical company. At Anacor, Mr. Ippolito was responsible for building marketing and sales functions, as well as developing the company's product portfolio. Prior to Anacor, he was Executive Vice President at Medicis Pharmaceutical, an industry-leading dermatology company. Over the course of his career, Mr. Ippolito has launched more than twenty brands in dermatology and he has played a leading role in two of the largest dermatology acquisitions of the past five years with combined valuations of $7.8 billion. Mr. Ippolito holds a B.A. in Business Administration, Management, and Operations from the University of Wisconsin with a minor in East Asian Studies from Sophia University in Japan.
Jim Lee joined Dermavant Sciences in 2016 from GSK where he served as head of the dermatology clinical development group since 2011. Dr. Lee began his career in pharmaceutical medicine over 17 years ago and has held positions of increasing responsibility in clinical development and medical affairs at GSK, Graceway Pharmaceuticals, Johnson and Johnson, and 3M Pharmaceuticals. His leadership and contributions in the development of a number of dermatological treatments, including Aldara and Stelara, have helped him become one of the leaders in dermatology development. Dr. Lee earned a B.A. in biochemistry from Carleton College, in Northfield, Minnesota and graduated from the Medical Scholars Program at the University of Illinois, receiving a Ph.D. in biochemistry and an M.D. from the College of Medicine.
David Rubenstein joined Dermavant in 2018 from GlaxoSmithKline Dermatology where he built an industry-leading dermatology drug development organization as VP, Discovery and Preclinical Development. Prior to GSK, he held academic roles at the University of North Carolina at Chapel Hill, most recently serving as the Louis C. Skinner Jr. Distinguished Professor of Dermatology. Dr. Rubenstein received his A.B. in Molecular Biology from Princeton University and his M.D. and Ph.D. from Duke University School of Medicine. He completed his dermatology residency and postdoctoral fellowship in dermatology and biology at UNC-Chapel Hill.
Richard Peterson joined Dermavant in 2018 from Sienna Biopharmaceuticals where he served as Chief Financial Officer. He has extensive experience in the dermatology space, previously serving as Chief Financial Officer of Novan and as Chief Financial Officer, Executive Vice President, and Treasurer of Medicis Pharmaceutical Corporation through the company’s $2.6 billion acquisition in 2012. Before joining Medicis in 1995, Mr. Peterson was a Senior Financial Auditor at PricewaterhouseCoopers LLP. He received his B.S. in Accounting from Arizona State University.
Ariel D. Jasie joined Dermavant in 2018 from Codiak BioSciences where he served as Chief Business Officer. Prior to Codiak, he served in various executive roles at Celgene Corporation, most recently as Executive Director for Strategy and Operations for the company’s Research & Early Development Group. Before joining Celgene, Mr. Jasie served as in-house counsel at Reliant Pharmaceuticals through the company’s $1.6 billion acquisition in 2007. He received his B.A. in History from the University of Maryland and his J.D. from Brooklyn Law School.
Chris Van Tuyl joined Dermavant in 2018 from Sacks Tierney P.A., where he was a partner in the firm’s corporate practice group. He previously served as Corporate Secretary, Chief Compliance Officer, and Associate General Counsel at Rayonier, Inc., where he oversaw key aspects of the company’s multi-billion-dollar spinoff of its chemicals business in 2014, and as Associate General Counsel at Medicis Pharmaceuticals through the company’s $2.6 billion acquisition in 2012. Prior to joining Medicis, Mr. Van Tuyl was a corporate attorney at Squire Sanders & Dempsey LLP in Phoenix and Clifford Chance LLP in New York. He received his B.S. in Finance summa cum laude from Arizona State University and his J.D. from Duke University School of Law.
Rebecca joined Dermavant Sciences in August 2016. Rebecca was previously employed at PAREXEL International, where she served as the Head of the GSK Business Unit. Rebecca also worked for GSK for twenty-four years, holding a variety of leadership positions across multiple therapy areas and across Phases II – IV in data management, clinical research and clinical operations, the last being Global Operations Head for Stiefel, a GSK company focused on dermatology. While with GSK, she supported multiple NDAs leading to approvals for Serevent®, Flovent®, Advair® and Breo®. Rebecca received her B.S. from Virginia Tech, and her M.A. from Duke University.
Jane Bethea serves as the Portfolio and Program Management Director at Dermavant Sciences. Jane joined Dermavant in August 2016 from Roivant Sciences, where she served as Project Management Director since March 2014. Prior to Roivant, she spent 14 years as a project manager at GlaxoSmithKline supporting both pre-clinical and clinical stage development programs. During that time, she also provided planning support for more than 14 regulatory submissions and worked on numerous development programs with external alliance partners. Jane received her BSBA from North Carolina Wesleyan College.
Adam joined Dermavant Sciences in June 2016 and leads medical affairs and business development efforts. Adam previously worked as a generalist in business development at Roivant Sciences, Inc., evaluating opportunities across the dermatology, women’s and men’s health, and rare disease spaces. Adam received his PhD in Molecular Biophysics and Biochemistry from Yale University, and his BA in Chemistry with highest honors and highest distinction from UNC-Chapel Hill.